Why Sponsor Oversight Failures in IMP Management Trigger Audit Findings

Introduction: The Sponsor’s Role in IMP Oversight

Sponsors are ultimately accountable for ensuring proper management of Investigational Medicinal Products (IMPs), even when tasks are delegated to CROs or investigator sites. IMP management covers receipt, storage, dispensing, reconciliation, return, and destruction. Regulatory agencies such as the FDA, EMA, and MHRA expect sponsors to maintain oversight of these activities. Failures in oversight frequently appear in audit findings, often leading to major observations that delay approvals or compromise trial data integrity.

Common oversight failures include missing IMP reconciliation checks, inadequate destruction documentation, and lack of sponsor verification of CRO or site practices. These gaps highlight weaknesses in sponsor governance and inspection readiness.

Regulatory Expectations for Sponsor IMP Oversight

Authorities outline strict expectations for sponsor responsibilities:

• Sponsors must verify IMP accountability at all sites through monitoring and audits.
• IMP management systems must comply with ICH GCP and 21 CFR Part 312.
• Oversight activities must be documented and stored in the Trial Master File (TMF).
• Reconciliation of dispensed versus returned IMP must be checked at regular intervals.
• Sponsors must confirm that CROs and sites follow SOPs for IMP handling, storage, and destruction.

The Indian Clinical Trials Registry (CTRI) reinforces sponsor accountability for investigational product oversight, noting that accountability cannot be fully delegated.

Common Audit Findings on Sponsor Oversight Failures

1. Incomplete IMP Reconciliation

Auditors frequently find discrepancies between dispensed and returned products without documented sponsor review.

2. Missing Documentation of Destruction

Audit reports often cite missing or unsigned IMP destruction certificates, indicating oversight weaknesses.

3. Lack of Verification of CRO Practices

Inspectors often note that sponsors did not audit or verify CRO IMP management systems.

4. Poor TMF Documentation

Oversight activities, reconciliation logs, and monitoring reports are frequently absent from the TMF, compromising inspection readiness.

Case Study: EMA Audit on Sponsor Oversight

In a Phase III cardiovascular trial, EMA inspectors discovered that the sponsor had not verified site IMP reconciliation practices for over six months. Discrepancies in dispensing and returns were not addressed, and destruction certificates were incomplete. The findings were categorized as critical, requiring immediate corrective measures and delaying the trial’s submission.

Root Causes of Sponsor Oversight Failures

Root cause investigations often identify:

• Over-reliance on CROs without sponsor verification of IMP activities.
• Absence of SOPs specifying sponsor oversight roles in IMP management.
• Lack of electronic systems for tracking accountability across multiple sites.
• Insufficient sponsor audits of IMP management processes.
• Resource constraints leading to inadequate sponsor review of IMP practices.